Cyclacel Stock Today

CYCC
 Stock
  

USD 1.46  0.14  10.61%   

Market Performance
6 of 100
Odds Of Distress
Less than 44
Cyclacel Pharmaceuti is trading at 1.46 as of the 3rd of October 2022, a 10.61 percent up since the beginning of the trading day. The stock's open price was 1.32. Cyclacel Pharmaceuti has about a 44 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Cyclacel Pharmaceuti are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of August 2022 and ending today, the 3rd of October 2022. Click here to learn more.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.. The company has 9.98 M outstanding shares of which 583.91 K shares are currently shorted by private and institutional investors with about 0.56 trading days to cover. More on Cyclacel Pharmaceuti
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Cyclacel Pharmaceuti Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cyclacel Pharmaceuti's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cyclacel Pharmaceuti or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Cyclacel Pharmaceuti is way too risky over 90 days horizon
Cyclacel Pharmaceuti may become a speculative penny stock
Cyclacel Pharmaceuti appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 150 K. Net Loss for the year was (19.72 M) with loss before overhead, payroll, taxes, and interest of (338 K).
Cyclacel Pharmaceuti currently holds about 29.64 M in cash with (21.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.marketscreener.com: CYCLACEL PHARMACEUTICALS, INC. Other Events - Marketscreener.com
CEOSpiro Rombotis
Average Analyst Recommendation
Analysts covering Cyclacel Pharmaceuti report their recommendations after researching Cyclacel Pharmaceuti's financial statements, talking to executives and customers, or listening in on Cyclacel Pharmaceuti's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Cyclacel Pharmaceuti. The Cyclacel consensus assessment is calculated by taking the average forecast from all of the analysts covering Cyclacel Pharmaceuti.
Strong Buy4 Opinions
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Cyclacel Pharmaceuti's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Cyclacel Pharmaceuti (CYCC) is traded on NASDAQ Exchange in USA and employs 12 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 13.17 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cyclacel Pharmaceuti's market, we take the total number of its shares issued and multiply it by Cyclacel Pharmaceuti's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Cyclacel Pharmaceuti conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 9.98 M outstanding shares of which 583.91 K shares are currently shorted by private and institutional investors with about 0.56 trading days to cover. Cyclacel Pharmaceuti currently holds about 29.64 M in cash with (21.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cyclacel Pharmaceuti Probability Of Bankruptcy
Ownership
Cyclacel Pharmaceuti retains a total of 9.98 Million outstanding shares. 30% of Cyclacel Pharmaceuti outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Cyclacel Ownership Details

Cyclacel Stock Price Odds Analysis

What are Cyclacel Pharmaceuti's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Cyclacel Pharmaceuti jumping above the current price in 90 days from now is about 41.4%. The Cyclacel Pharmaceuti probability density function shows the probability of Cyclacel Pharmaceuti stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Cyclacel Pharmaceuti has a beta of 0.9772 suggesting Cyclacel Pharmaceuti market returns are sensitive to returns on the market. As the market goes up or down, Cyclacel Pharmaceuti is expected to follow. Additionally, the company has an alpha of 0.3933, implying that it can generate a 0.39 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 1.46HorizonTargetOdds Above 1.46
58.50%90 days
 1.46 
41.40%
Based on a normal probability distribution, the odds of Cyclacel Pharmaceuti to move above the current price in 90 days from now is about 41.4 (This Cyclacel Pharmaceuti probability density function shows the probability of Cyclacel Stock to fall within a particular range of prices over 90 days) .

Cyclacel Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Cyclacel Pharmaceuti that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cyclacel Pharmaceuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cyclacel Pharmaceuti's value.
InstituionSecurity TypeTotal SharesValue
Schonfeld Strategic Advisors LlcCommon Shares514.5 K556 K
Sio Capital Management LlcCommon Shares454.4 K491 K
Schonfeld Strategic Advisors LlcCall Options100 K108 K
View Cyclacel Pharmaceuti Diagnostics

Cyclacel Pharmaceuti Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cyclacel Pharmaceuti market risk premium is the additional return an investor will receive from holding Cyclacel Pharmaceuti long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cyclacel Pharmaceuti. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cyclacel Pharmaceuti's alpha and beta are two of the key measurements used to evaluate Cyclacel Pharmaceuti's performance over the market, the standard measures of volatility play an important role as well.

Cyclacel Stock Against Markets

Picking the right benchmark for Cyclacel Pharmaceuti stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Cyclacel Pharmaceuti stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Cyclacel Pharmaceuti is critical whether you are bullish or bearish towards Cyclacel Pharmaceuti at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cyclacel Pharmaceuti without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Exposure Probability Now

   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Cyclacel Pharmaceuti Corporate Directors

Cyclacel Pharmaceuti corporate directors refer to members of a Cyclacel Pharmaceuti board of directors. The board of directors generally takes responsibility for the Cyclacel Pharmaceuti's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Cyclacel Pharmaceuti's board members must vote for the resolution. The Cyclacel Pharmaceuti board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Nicholas Bacopoulos - Independent DirectorProfile
Lloyd Sems - Independent DirectorProfile
Samuel Barker - DirectorProfile
Gregory Hradsky - Independent DirectorProfile

Invested in Cyclacel Pharmaceuti?

The danger of trading Cyclacel Pharmaceuti is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Cyclacel Pharmaceuti is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Cyclacel Pharmaceuti. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Cyclacel Pharmaceuti is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Cyclacel Pharmaceuti information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuti price analysis, check to measure Cyclacel Pharmaceuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuti is operating at the current time. Most of Cyclacel Pharmaceuti's value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuti's price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuti to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is Cyclacel Pharmaceuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuti. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cyclacel Pharmaceuti is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuti's value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuti's market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.